RecruitingPhase 3NCT05511363
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Allentown, PA · +58 more sites